Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

J Clin Oncol. 2022 Apr 20;40(12):1271-1274. doi: 10.1200/JCO.22.00204. Epub 2022 Mar 3.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Chemoradiotherapy / adverse effects
  • Humans
  • Lung Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal
  • durvalumab